Cardio3 BioSciences Announces Results of Annual Shareholder

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Cardio3 BioSciences Announces Results of Annual Shareholder Assembly 2015 and Confirmation of Name Change to Celyad

MONT-SAINT-GUIBERT, Belgium, May 5, 2015 (GLOBE NEWSWIRE) -- Cardio3 BioSciences ("the Company") (Brussels: CARD ) (Paris: CARD ) a leader in the discovery and development of engineered cell therapies, today announced that all resolutions presented at the Company's Annual Shareholder Assembly were duly passed at the meeting, which was held today at 09:00 CET.

As a result, the Company's proposed name change to "Celyad" is now confirmed, effective immediately. The new corporate website is available online at www.celyad.com . Furthermore, as of 09:00 CET on 6 May 2015, the Company will trade on the Euronext Brussels and Paris regulated markets under the symbol CYAD, replacing former symbol CARD. No specific action is required from our shareholders following this symbol change.

The Company is also pleased to announce that copies of the 2014 Annual Report and Accounts will be made available to shareholders on the "Investors" section of the Company's website at www.celyad.com , and paper copies will be made available upon request to the Company.

For more information, please contact:

Celyad SA Christian Homsy, CEO Julie Grade, Corporate Communications Manager www.celyad.com Tel: +32 10 39 41 00 jgrade@celyad.com
For Europe: Consilium Strategic Communications Amber Bielecka, Chris Welsh, Laura Thornton Tel : +44 20 3709 5700 celyad@consilium-comms.com
For the U.S: The Ruth Group Lee Roth (Investors), Kirsten Thomas (Media) Tel: +1 646 536 7012 / 7014 celyad@theruthgroup.com
   

To subscribe to Celyad's newsletter, visit www.celyad.com .

Follow us on Twitter @CelyadSA

About Celyad

Founded in 2007, and based in Belgium, Celyad is a leader in engineered cell therapy with clinical programs initially targeting indications in cardiology and oncology. Celyad is developing its lead cardiovascular disease product candidate, C-Cure®, for the treatment of ischemic heart failure, and has completed enrolment of a Phase III trial in Europe and Israel. In addition, the Company is developing a novel portfolio of CAR T-cell therapies that utilize human Natural Killer cell receptors for the treatment of numerous blood and solid cancers. Its lead oncology product candidate, NKG2D CAR T-cell, entered a Phase I clinical trial in April 2015.

Celyad's shares are listed on Euronext Brussels and Euronext Paris under the ticker symbol CYAD.

To learn more about Celyad, please visit www.celyad.com

Forward looking statements

In addition to historical facts or statements of current condition, this press release contains forward-looking statements, which reflect our current expectations and projections about future events, and involve certain known and unknown risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. These forward-looking statements are further qualified by important factors, which could cause actual results to differ materially from those in the forward-looking statements, including timely submission and approval of anticipated regulatory filings; the successful initiation and completion of clinical trials, including Phase III clinical trials for C-Cure® and Phase I clinical trial for NKG2D CAR T-Cell additional clinical results validating the use of adult autologous stem cells to treat heart failure and CAR T-cell autologous therapy to treat cancer; satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; obtaining, maintaining and protecting intellectual property, our ability to enforce our patents against infringers and defend our patent portfolio against challenges from third parties, competition from others developing products for similar uses, our ability to manage operating expenses, and our ability to obtain additional funding to support our business activities and establish and maintain strategic business alliances and business initiatives. Any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.

C3BS-CQR-1, C-Cure, NKG2D CAR T-Cell, C-Cath ez , OnCyte, Celyad, Cardio3 BioSciences and the Cardio3 BioSciences, Celyad, C-Cath ez , CHART-1, CHART-2 and OnCyte logos are signs internationally protected under applicable Intellectual Property Laws. Mayo Clinic holds equity in Celyad as a result of intellectual property licensed to the company.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 19

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
MISUMI Americas Expands, Ventures into New Horizons

Updated Category News Views 84

Marking New Territory in Monterrey MISUMI Americas is planting a new flag down in Monterrey, Mexico, with a sprawling 45,000-square-foot facility. This isn't just another expansion; it's a strategic move that's bound to shake things up in the manufacturing sector south of the border. When you've got a player like MISUMI widening their footprint, it catches the eye. Why?...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 25

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 74

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading
Sue Egstrand to Lead Karo's Next Growth Phase

Updated Category News Views 152

A New Captain at Karo’s Helm Karo Healthcare is bracing for an exciting ride. Sue Egstrand’s appointment as the new CEO pulls the curtain on what might just be a game-changing era for the company. Set to take the wheel on January 1, 2027, Egstrand brings a heavy-hitting resume—a mash-up of pharmaceutical prowess and a deep-dive into consumer healthcare. Sue’s...

Continue Reading
CICYBELL's Black Friday Is a Fashionist's Dream

Updated Category News Views 130

Stepping Into the Fashion Frenzy It’s that time of year again, where shoppers are girding up for Black Friday. And here comes CICYBELL, ready to dish up some meaty discounts that would turn even the most hardened cynic into a frenzied shopper. Alright, maybe that’s a touch dramatic, but let’s break down what this fashion brand is cooking up in their latest sale....

Continue Reading
Carolina Pines Tackles Rural Healthcare Myths on TV

Updated Category News Views 133

Rural Healthcare Battles the Big City Myth Picture this: you're in a tiny town where everyone knows your dog's name, but some think you've got to head to the city for top-notch medical care. That's where Carolina Pines Regional Medical Center steps in. They’ve snagged a spot on 'All Access with Andy Garcia', shining a light on how investments in tech and talent keep...

Continue Reading
Choate's Expands to New Mid-South Markets

Updated Category News Views 21

Family Traditions Drive Choate's Growth Back in the day, you might've thought the family-run businesses were a dying breed, right? Not in the case of Choate's Air Conditioning, Heating, Plumbing & Electrical. These folks aren't just holding the fort; they're storming new territories across the Mid-South like they've got something to prove—or maybe just something to...

Continue Reading
Qfin Holdings Faces Securities Fraud Lawsuit Scrutiny

Updated Category News Views 23

Qfin Holdings Stumbles Under Legal Microscope Picture this—you're riding the stock market wave and then, out of nowhere, your investment gets hit by a sudden drop, leaving you scrambling for answers. That's the scenario investors in Qfin Holdings, Inc. (NASDAQ: QFIN) find themselves in after the company’s stock plunged by nearly 19%. Now, they're not just left...

Continue Reading
AI Alliance Rethinks Health Plan Engagement

Updated Category News Views 44

Building Bridges in Healthcare Ever seen healthcare stuck in its own muck with disconnected gears attempting to move the same machine? Well, that's precisely the mountain healthplans.ai and URAWARRIOR aim to climb down from. Founders Rachel Spilo and Dr. Bershan Shaw are gearing up to shake hands in their no-nonsense, real-world vow to sync member engagement with the...

Continue Reading

Top 5 Most Recently Viewed Articles

Aura Minerals Inc. Successfully Issues New Brazilian Debentures

Updated Category News Views 55

Aura Minerals Inc. Successfully Secures Funding through Debenture Issuance Aura Minerals Inc. (TSX: ORA) has recently made waves in the financial sector by successfully concluding the public offering of its 2nd issuance of debentures. The company announced this development following previous communications made on several dates earlier this year, confirming the completion...

Continue Reading
Emerging Trends in Clinical Trials Matching Software Market

Updated Category News Views 266

Growth of the Clinical Trials Matching Software Market The landscape of clinical trials is continually evolving, with the clinical trials matching software market expected to reach an impressive USD 501.86 million. This expansion points to a noteworthy compound annual growth rate (CAGR) of 13.14% between 2025 and 2032. Significance of AI and EHR Integration Market...

Continue Reading
Greystone Housing Plans Earnings Call to Discuss Q1 Results

Updated Category News Views 155

Greystone Housing to Host Earnings Conference Call Greystone Housing Impact Investors LP (NYSE: GHI) has announced it will be hosting an important earnings conference call for investors. This event is set to take place on a Wednesday at 4:30 p.m. Eastern Time. The focus of the call will be on discussing the financial results from the first quarter of the year....

Continue Reading
Successful Toyota Dealership Sale in the Automotive Market

Updated Category News Views 864

Performance Brokerage Services Facilitates Dealership Transaction Performance Brokerage Services, a leader in dealership buy-sell activities, has announced the successful sale of Premier Toyota. The dealership changed ownership from Robert Fisher to Kevin Wuepper, showcasing the brokerage firm’s expertise in the automotive sector. The Journey of Premier Toyota Founded...

Continue Reading
Investigation Launched into Sealed Air Corporation's Shareholder Deal

Updated Category News Views 193

Understanding the Investigation of Sealed Air Corporation In recent news, the Ademi Firm has initiated a probe into Sealed Air Corporation (NYSE: SEE), focusing on their proposed transaction with CD&R. This investigation is crucial because it centers on possible violations of fiduciary duty and legal requirements by the company’s board. The goal is to ensure that...

Continue Reading